Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Profiling of Blood Transcriptome Predicts Complications in Pregnancies

By LabMedica International staff writers
Posted on 15 Apr 2019
Researchers have proposed profiling of the blood transcriptome as a method to predict complications in pregnancy that might be experienced by women with systemic lupus erythematosus.

Systemic lupus erythematosus carries an increased risk of pregnancy complications, including preeclampsia and fetal adverse outcomes. More...
To identify the underlying molecular mechanisms responsible for this risk, investigators at Weill Cornell Medicine (New York, NY, USA) longitudinally profiled the blood transcriptome of 92 lupus patients and 43 healthy women during pregnancy and postpartum and performed multicolor flow cytometry in a subset of them.

The transcriptome is the set of all RNA molecules in a cell or a population of cells. It is sometimes used to refer to all RNAs, or just mRNA, depending on the particular experiment. It differs from the exome in that it includes only those RNA molecules found in a specified cell population, and usually includes the amount or concentration of each RNA molecule in addition to the molecular identities. Since it includes all mRNA transcripts in the cell, the transcriptome reflects the genes that are being actively expressed at any given time.

The investigators also profiled 25 healthy women undergoing assisted reproductive technology to monitor transcriptional changes around the time of embryo implantation.

Results indicated that during healthy pregnancy there was a sustained down-regulation of multiple immune signatures, including interferon and plasma cells. These changes appeared early after embryo implantation and were mirrored in uncomplicated lupus pregnancies. Patients with preeclampsia displayed early up-regulation of neutrophil signatures that correlated with expansion of immature neutrophils.

Lupus pregnancies with fetal complications carried the highest interferon and plasma cell signatures as well as activated CD4+ T-cell counts. Therefore, blood immunomonitoring revealed that both healthy and uncomplicated lupus pregnancies exhibited early and sustained transcriptional modulation of lupus-related signatures. Lack of this modulation was associated with adverse outcomes.

"Overall, we have identified significant changes in immune pathways during healthy pregnancy and found that failure to modulate them properly is associated with complications in pregnant lupus patients," said senior author Dr. Virginia Pascual, professor of pediatrics at Weill Cornell Medicine. "Our findings provide a framework for future studies aimed at developing therapeutic strategies to improve health outcomes for mothers with lupus and their offspring."

The work was published in the April 8, 2019, online edition of the Journal of Experimental Medicine.

Related Links:
Weill Cornell Medicine


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.